Bristol-Myers Squibb Announces Early Settlement of Tender Offers for Debt Refinancing

Details

The company decreased the maximum aggregate purchase price for Pool 1 Notes to accept all validly tendered notes and increased the price for Pool 2 Notes to accept notes with priority levels 1 through 4, as well as up to $250 million of 5.900% Notes due 2033. The Early Tender Deadline was set for 5:00 p.m. on November 17, 2025, and the Offers are subject to the terms of the Offer to Purchase dated November 3, 2025.

Items reported

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.